Bristol Myers Squibb makes Singapore its Asia hub

Bristol Myers Squibb names Singapore as its new Pan Asia Hub, strengthening its 60-year legacy in the country

The company reinforces its commitment to Singapore to advance the local life sciences ecosystem, focusing on innovation, clinical research, and talent development.

08 Jul 2026 2 min read

This press release was issued by Bristol Myers Squibb.

Bristol Myers Squibb (BMS), a global biopharmaceutical leader, today celebrated its 60th anniversary in Singapore by recognizing it as a new Pan Asia Cluster (PAC) hub for the company. Supported by the Singapore Economic Development Board (EDB), the hub will accelerate patient access and innovation in the region and see the addition of key talent based in Singapore.

Speaking at the celebration event, Steve Sugino, Senior Vice President, Asia Pacific, BMS spotlighted the company’s long-term commitment to Singapore.

“Our 60-year legacy in Singapore is proof of our long-term commitment to bringing innovative medicines to patients here and across the region. Establishing Singapore as a Pan Asia Cluster hub reflects the growing importance of the region in our global strategy. We value our work with partners like the Singapore Economic Development Board to support the growth of a vibrant life sciences ecosystem and, most importantly, improve patient access to innovative medicines for years to come.”

Steve Sugino

Senior Vice President, Asia Pacific

Bristol Myers Squibb

A Strong Endorsement of Singapore’s Position

BMS’s commitment recognizes Singapore as a stable, innovative and future-ready base in Asia. BMS’s decision to deepen its roots in Singapore underscores its confidence in the nation’s strong life sciences ecosystem, skilled talent base and role as a strategic regional hub.

“We congratulate Bristol Myers Squibb on its 60th anniversary in Singapore and welcome its continued growth here. The establishment of its new Pan Asia Cluster hub adds to Singapore’s vibrant biomedical sciences ecosystem, and reinforces our role as a trusted base for companies to drive innovation and regional strategies. We look forward to deepening our partnership with Bristol Myers Squibb as it advances clinical research and brings innovative medicines to patients in Singapore and across the region.”

Ho Weng Si

Executive Vice President

EDB

Bringing Access to Patients Closer to Home

The hub, which currently employs over 200 employees, brings together markets including Hong Kong & Macau, Taiwan, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines. The hub will strengthen capabilities and talent at scale, strategically leveraging partnerships and delivering enhanced patient impact.

Currently, BMS has more than 60 clinical trials in the PAC region, with five new trials targeted to start in Singapore by end of 2026. The move reinforces Singapore’s role in improving access to innovative medicines and healthcare outcomes across the region. For patients, the impact of such efforts are significant. Innovation, access and education all contribute to earlier diagnosis, better care and improved outcomes.

“For the patients and families we journey alongside, advances in cancer care mean more than better clinical outcomes. They mean more time, a better quality of life, and the opportunity to live well beyond cancer. That is the real impact of continued innovation.”

Tan Kwang Cheak

Chief Executive Officer

Singapore Cancer Society

Following its support in 2025, BMS is proud to once again participate in the Singapore Cancer Society's Race Against Cancer this year as a Silver Partner.